M
Mansour T. A. Sharabiani
Researcher at Imperial College London
Publications - 50
Citations - 1578
Mansour T. A. Sharabiani is an academic researcher from Imperial College London. The author has contributed to research in topics: Prostate cancer & Gibbs sampling. The author has an hindex of 14, co-authored 45 publications receiving 1132 citations. Previous affiliations of Mansour T. A. Sharabiani include National Institutes of Health & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Systematic review of comorbidity indices for administrative data.
TL;DR: The performance of a given comorbidity measure depends on the patient group and outcome, and the Elixhauser index seems the best so far, particularly for mortality beyond 30 days, although several newer, more inclusive measures are promising.
Journal ArticleDOI
Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis.
Pengwei Hu,Kanika I. Dharmayat,C. Stevens,Mansour T. A. Sharabiani,Rebecca Jones,Gerald F. Watts,Gerald F. Watts,Jacques Genest,Kausik K. Ray,Antonio J. Vallejo-Vaz +9 more
TL;DR: With an overall prevalence of 1:311, FH is among the commonest genetic disorders in the GP, similarly present across different regions of the world, and is more frequent among those with ASCVD.
Journal ArticleDOI
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Vincenza Conteduca,Daniel Wetterskog,Mansour T. A. Sharabiani,Enrique Grande,M.P. Fernandez-Perez,Anuradha Jayaram,Anuradha Jayaram,Samanta Salvi,Daniel Castellano,Alessandro Romanel,C. Lolli,Valentina Casadio,Giorgia Gurioli,Dino Amadori,Antoni Font,Sergio Vazquez-Estevez,A. González del Alba,Begoña Mellado,O. Fernandez-Calvo,M.J. Méndez-Vidal,Miguel Angel Climent,Ignacio Duran,Enrique Gallardo,Armando Rodríguez,Carmen Santander,Marc Saez,Javier Puente,D. Gasi Tandefelt,Anna Wingate,David P. Dearnaley,David P. Dearnaley,Francesca Demichelis,Francesca Demichelis,U. De Giorgi,Enrique Gonzalez-Billalabeitia,Enrique Gonzalez-Billalabeitia,Gerhardt Attard,Gerhardt Attard +37 more
TL;DR: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone and Prospective evaluation of treatment decisions based on plasma AR is now required.
Journal ArticleDOI
Aortic Valve Replacement and the Ross Operation in Children and Young Adults
Mansour T. A. Sharabiani,Dan M Dorobantu,Alireza S. Mahani,Mark Turner,Andrew Tometzki,Gianni D Angelini,Andrew J. Parry,Massimo Caputo,Serban Stoica +8 more
TL;DR: AVR in the young achieves good results, with the Ross being overall better suited for this age group, especially in children, and the need for homograft reinterventions is an issue to take into account.
Journal ArticleDOI
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
Alison Tree,Kelly Jones,Shaista Hafeez,Mansour T. A. Sharabiani,Kevin J. Harrington,Susan Lalondrelle,Merina Ahmed,Robert Huddart +7 more
TL;DR: The PLUMMB trial met the protocol-defined definition of dose-limiting toxicity and will be amended to reduce radiation therapy dose, particularly when radiation therapy is given at high dose per fraction for pelvic tumours.